Sarepta presents DM1 data as Sarepta Therapeutics stock trades at EUR 15.03

Published on 10/15/2026 at 13:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sarepta presented SRP-1003 data on October 14, 2026, showing 80 percent knockdown. Sarepta Therapeutics stock costs EUR 15.03 on October 15, 2026.

New RNA program adds context

SRP-1003 achieved up to 80 percent knockdown in preclinical models on October 14, 2026.
Single-dose exposure lasted up to 16 weeks in preclinical muscle studies.
Sarepta Therapeutics stock trades at EUR 15.03 at 1:41 p.m. CEST at Lang & Schwarz on October 15, 2026.
Second-quarter 2026 revenue reached USD 401.25 million, down 34.3 percent year over year.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) presented new SRP-1003 data on October 14, 2026, showing up to 80 percent knockdown of pathogenic DMPK messenger RNA in both the nucleus and cytoplasm of preclinical models. The announcement gives investors a new pipeline measure beyond the company's Duchenne muscular dystrophy franchise.

SRP-1003 reaches both cell compartments

According to Sarepta Therapeutics, SRP-1003 reduced pathogenic DMPK messenger RNA in a dose-dependent way, reaching up to 80 percent knockdown in each compartment. The program also corrected disease-related mis-splicing and reduced toxic RNA foci in patient-derived muscle cells and mouse models.

The company said pharmacokinetic studies found sustained exposure across several upper and lower body muscle groups for up to 16 weeks after a single intravenous dose. SRP-1003 is being evaluated in a Phase 1/2 study involving adults with myotonic dystrophy type 1, so the evidence remains preclinical while the human study continues.

What does the pipeline add?

The pipeline update matters because Sarepta's latest reported quarter combined strong adjusted earnings with weaker sales. MarketBeat reported second-quarter 2026 revenue of USD 401.25 million, down 34.3 percent from the prior year, while adjusted earnings per share reached USD 0.64 against a USD 0.22 consensus estimate.

Markets Insider said GAAP net loss was USD 4.89 million in the quarter, compared with USD 196.89 million of net income in the year-earlier period. For investors, the central tension is clear: pipeline progress must develop alongside a recovery in commercial revenue.

Stock price and valuation context

Sarepta Therapeutics stock was trading at EUR 15.03 at Lang & Schwarz on October 15, 2026 at 1:41 p.m. CEST. The primary listing is on Nasdaq, where the stock last stood at USD 16.83 on October 14, 2026, while its 52-week range was USD 14.68 to USD 24.68. The market capitalization was USD 1.8 billion as of October 15, 2026.

The further course of trading is shown by the continuously updated real-time quote of Sarepta Therapeutics stock.